The goals of this project are to build an experimental tool to dissect out in vivo pancreatic beta cell mass (BCM) and beta cell function (BCF) and to assess for the first time these two determinants of beta cell functional mass (BCFxM) in obesity and in various stages of type 1 and type 2 diabetes mellitus.

开始日期2022-03-15

申办/合作机构

Azienda Ospedaliero-Universitaria di Parma

[+1]

100 项与 68Ga-exendin-4 相关的临床结果

登录后查看更多信息

100 项与 68Ga-exendin-4 相关的转化医学

登录后查看更多信息

100 项与 68Ga-exendin-4 相关的专利（医药）

登录后查看更多信息

项与 68Ga-exendin-4 相关的文献（医药）

2024-05-01·Indian journal of endocrinology and metabolism

Diagnostic Modalities, Management Considerations, and Outcomes of Insulinoma: A Case Series from a Tertiary Care Centre

Article

作者: Walia, Rama ; Das, Liza ; Behera, Arunanshu ; Shetty, Anirudh J. ; Rana, Surinder S. ; Jayant, Satyam S. ; Saikia, Uma N. ; Gulati, Ajay ; Dutta, Pinaki ; Kumar, Rajender ; Bhadada, Sanjay K. ; Singh, Harmandeep ; Mittal, Bhagwant R.

Abstract:

Introduction::

Insulinomas are rare, usually sporadic, and typically benign pancreatic neuroendocrine tumours. Pre-operative localization is challenging and evidence on comparative analysis of anatomic and scintigraphic modalities for pre-operative tumour localization is limited, even in contemporary series.

Methods::

The current study was designed to study the clinical features and management challenges of insulinomas managed at a tertiary care centre. Clinical features, diagnosis, imaging techniques, surgical procedures, and outcomes details were collated. Pre-operative imaging techniques (CT/MRI, nuclear scintigraphy) were compared with intraoperative and histopathological findings to assess their accuracy of localization.

Results::

Thirty-seven patients (15 females [42%]; median age 36 years [IQR 28–49]) were included in the study. In four patients (10.8%), the tumour occurred in the setting of multiple endocrine neoplasia type 1 (MEN 1) while the remaining were sporadic. The sensitivity of pre-operative localization was 61.5% (multiphasic CT), 66.6% (multiphasic MRI), 100% (68Ga Exendin-4 PET-CT), and 91.6% (EUS). Three patients with normal multiphasic CT had localization on 68Ga Exendin-4 PET-CT. The positive predictive value (PPV) of both Exendin-PET-CT and EUS was similar at 91.6% and 91.6%, respectively. All patients (except one with nesidioblastosis), who underwent enucleation or partial pancreatic resection, were cured.

Conclusion::

68Ga Exendin-4 PET-CT based is a non-invasive imaging modality that has high sensitivity and PPV and can be used as a first-line imaging modality. The overall prognosis of these tumours is good with high cure rates attained following surgical resection.

2023-07-01·Diabetes

Monitoring β-Cell Survival After Intrahepatic Islet Transplantation Using Dynamic Exendin PET Imaging: A Proof-of-Concept Study in Individuals With Type 1 Diabetes.

Article

作者: de Galan, Bastiaan E ; Eriksson, Olof ; de Koning, Eelco J P ; van Koeverden, Sebastiaan ; Gotthardt, Martin ; van der Graaf, Marinette ; Brom, Maarten ; Velikyan, Irina ; Jansen, Theodorus J P ; Vantyghem, Marie-Christine ; Buitinga, Mijke ; Engelse, Marten A ; Nijhoff, Michiel F ; Pattou, François ; Beron, Amandine ; Boss, Marti

ARTICLE HIGHLIGHTS:

This clinical study researched the potential of radiolabeled exendin to follow the fate and survival of intrahepatic islet grafts. Is it feasible to quantitatively detect intrahepatic islet transplants with [68Ga]Ga-NODAGA-exendin-4 (68Ga-exendin) positron emission tomography (PET) imaging? Our study findings indicate that the imaging technique 68Ga-exendin PET can be used to monitor viable islet mass after intrahepatic islet transplantation in humans. Alongside functional measures, 68Ga-exendin PET imaging could significantly aid in the evaluation of strategies designed to improve islet engraftment, survival, and function.

2022-03-01·Journal of nuclear medicine : official publication, Society of Nuclear Medicine1区 · 医学

Value of ⁶⁸Ga-DOTATOC and Carbidopa-Assisted ¹⁸F-DOPA PET/CT for Insulinoma Localization

1区 · 医学

Article

作者: Addeo, Pietro ; Imperiale, Alessio ; Boursier, Caroline ; Sebag, Frédéric ; Ouvrard, Eric ; Taïeb, David ; Sahakian, Nicolas ; Chevalier, Elodie

Our objective was to assess the value of ⁶⁸Ga-DOTATOC and carbidopa-assisted ¹⁸F-fluorodihydroxyphenylalanine (¹⁸F-DOPA) in 21 hypoglycemic patients. Methods: All patients who underwent ⁶⁸Ga-DOTATOC or carbidopa-assisted ¹⁸F-DOPA PET/CT for suspicion of insulinoma from January 2019 to January 2021 were retrospectively analyzed. A final diagnosis of insulinoma was determined by pathologic reports or consensus. Results: During the study period, 21 patients underwent both ⁶⁸Ga-DOTATOC and ¹⁸F-DOPA PET/CT. A final diagnosis of insulin-secreting tumor was reached in 12 cases, including 11 insulinomas and 1 small mixed neuroendocrine/nonneuroendocrine neoplasm. ¹⁸F-DOPA and ⁶⁸Ga-DOTATOC PET/CT were positive in 5 (45%) and 7 (64%) of 11 cases, respectively, with 4 concordant positive findings. Moreover, 1 insulinoma was visualized exclusively by ¹⁸F-DOPA PET/CT and 3 by ⁶⁸Ga-DOTATOC PET/CT only. ¹⁸F-DOPA and ⁶⁸Ga-DOTATOC PET/CT were falsely positive in 1 nonfunctioning pancreatic neuroendocrine tumor. Conclusion: When ⁶⁸Ga-exendin-4 is not available, ⁶⁸Ga-somatostatin receptor PET/CT should be the first choice for insulinoma functional imaging.

100 项与 68Ga-exendin-4 相关的药物交易

登录后查看更多信息